SCHEMBL5815739

SCHEMBL5815739

CCOC(=O)C1=C(C)NC2=C(C(=O)CC(C)(C)C2)C1C1CCCC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.61
NPSR1 Q6W5P4 4/20 0.61
MEN1 O00255 1/20 0.61
KMT2A Q03164 1/20 0.61
KDM4E B2RXH2 15/20 0.56
ALDH1A1 P00352 11/20 0.56
GAA P10253 8/20 0.56
HSD17B10 Q99714 6/20 0.56
CASP1 P29466 5/20 0.56
RECQL P46063 1/20 0.56
HPGD P15428 4/20 0.55
CASP7 P55210 4/20 0.55
GLA P06280 3/20 0.55
USP2 O75604 2/20 0.50
ALOX15 P16050 1/20 0.50
MCL1 Q07820 1/20 0.50
HTT P42858 1/20 0.49
NCOA1 Q15788 1/20 0.49
NCOA3 Q9Y6Q9 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6029208 0.99 NPSR1 (0.62) TSHRNPSR1MEN1KMT2AKDM4E
SCHEMBL5816033 0.95 KDM4E (0.58) TSHRNPSR1MEN1KMT2AKDM4E
SCHEMBL6027944 0.91 NPSR1 (0.52) TSHRNPSR1MEN1KMT2AKDM4E
SCHEMBL17198741 0.85 ALDH1A1 (0.63) TSHRNPSR1MEN1KMT2AKDM4E
SCHEMBL6028433 0.84 HTT (0.54) TSHRNPSR1MEN1KMT2AKDM4E
SCHEMBL6027547 0.84 NPSR1 (0.56) TSHRNPSR1MEN1KMT2AKDM4E
SCHEMBL5821977 0.84 NPSR1 (0.53) TSHRNPSR1MEN1KMT2AKDM4E
SCHEMBL973105 0.83 TSHR (0.56) TSHRNPSR1MEN1KMT2AKDM4E
SCHEMBL6027946 0.83 KDM4E (0.56) TSHRNPSR1KDM4EALDH1A1GAA
SCHEMBL6027988 0.83 TSHR (0.52) TSHRNPSR1MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1663227-A2 DIHYDROPYRIDINE COMPOUNDS FOR TREATING OR PREVENTING METABOLIC DISORDERS Synta Pharmaceuticals Corporation (US) 2006-06-07 EP claimed
US-20050203119-A1 Dihydropyridine compounds for treating or preventing metabolic disorders SYNTA PHARMACEUTICAL CORP. 2005-09-15 US claimed
WO-2005025507-A2 DIHYDROPYRIDINE COMPOUNDS FOR TREATING OR PREVENTING METABOLIC DISORDERS SYNTA PHAMACEUTICALS CORP. (US) 2005-03-24 WO claimed
WO-2006065842-A2 5,6,7,8-TETRAHYDROQUINOLINES AND RELATED COMPOUNDS AND USES THEREOF SYNTA PHARMACEUTICALS CORP. (US) 2006-06-22 WO disclosed
EP-1663227-A2 DIHYDROPYRIDINE COMPOUNDS FOR TREATING OR PREVENTING METABOLIC DISORDERS Synta Pharmaceuticals Corporation (US) 2006-06-07 EP disclosed
US-20050203119-A1 Dihydropyridine compounds for treating or preventing metabolic disorders SYNTA PHARMACEUTICAL CORP. 2005-09-15 US disclosed
WO-2005025507-A2 DIHYDROPYRIDINE COMPOUNDS FOR TREATING OR PREVENTING METABOLIC DISORDERS SYNTA PHAMACEUTICALS CORP. (US) 2005-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203119-A1 Dihydropyridine compounds for treating or preventing metabolic disorders SLC5A2, SLC5A1, QDPR TSHR 2744/4885NPSR1 703/4885MEN1 919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.